/ Published in 2019, Publication

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data from a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.

Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, Kapiga S, Grosskurth H, Kalluvya S, Bockstal V, Anumendem D, Luhn K, Robinson C, Douoguih M, Watson-Jones D.

J Infect Dis 2019; 220:46-56.

PMID:30796818

PMCID:PMC6548900

DOI:10.1093/infdis/jiz070

Related citation

What you can read next

“Ashamed of being seen in an HIV clinic”: a qualitative analysis of barriers to engaging in HIV care from the perspectives of patients and healthcare workers in the Daraja clinical trial.
Comparing Life’s Simple Seven between newly diagnosed, ART-naive people living with HIV and HIV-uninfected adults in Tanzania: clues for cardiovascular disease prevention.
The health of adolescents in sub-Saharan Africa: Challenges and opportunities. Ross DA, Mshana G, Guthold R. Trop Med Int Health. 2021 Jul 16. DOI: 10.1111/tmi.13655. PMID: 34270838.